Carbylan was founded in 2005 to develop and market medical devices and device/drug combination products based on novel, chemically-engineered polymer systems incorporating hyaluronic acid, a well known polysaccharide widely present in the human body. Its initial market focus is therapeutic medical devices and combination products to treat the pain associated with osteoarthritis. Carbylan biopolymers are biocompatible, non-immunogenic and, when combined with pharmaceutical agents, are designed to enable unique, controlled, local drug delivery with sustained therapeutic benefit. Carbylan is based in Palo Alto, California.